AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33982473 — intervention group
Group type: EXPERIMENTAL
Intervention: Certain herbal preparation for the treatment of non-severe influenza
Number of subjects: 0
Study 33982473 — intervention group
Group type: COMPARATOR
Intervention: Internationally recognized positive drugs or guidelines
Number of subjects: 0
Study 32667982 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin
Number of subjects: 104
Study 32667982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 32667982 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin (modified intention-to-treat)
Number of subjects: 104
Study 32667982 — intervention group
Group type: COMPARATOR
Intervention: Placebo (modified intention-to-treat)
Number of subjects: 104
Study 35589362 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitu app
Number of subjects: 90
Study 32546012 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour monitoring
Number of subjects: 186
Study 32546012 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit monitoring
Number of subjects: 186
Study 32546012 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrelevant behaviour monitoring
Number of subjects: 186
Study 32546012 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued behaviour
Number of subjects: 186
Study 32546012 — intervention group
Group type: EXPERIMENTAL
Intervention: Not cued behaviour
Number of subjects: 186
Study 32546012 — intervention group
Group type: COMPARATOR
Intervention: Post-intervention measures
Number of subjects: 186
Study 32423408 — intervention group
Group type: EXPERIMENTAL
Intervention: RIPASA score
Number of subjects: 79
Study 32423408 — intervention group
Group type: COMPARATOR
Intervention: Tzanakis score
Number of subjects: 79
Study 36286314 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 240
Study 36286314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 33420076 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological network
Number of subjects: 0
Study 33420076 — intervention group
Group type: COMPARATOR
Intervention: Randomized counterpart of the E. coli transcription network
Number of subjects: 0
Study 33935219 — intervention group
Group type: EXPERIMENTAL
Intervention: Four Square Step Test (FSST) performance
Number of subjects: 40
Study 33935219 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive tests (3MS, HVOT, TMT-B)
Number of subjects: 40
Study 33935219 — intervention group
Group type: EXPERIMENTAL
Intervention: Fracture characteristics (fracture side and type)
Number of subjects: 40
Study 35649597 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-fatigue assessment group using the Borg Exercise Scale to assess fatigue, stopping activity at fatigue level 5-6.
Number of subjects: 552
Study 35649597 — intervention group
Group type: COMPARATOR
Intervention: Fixed activity distance assessment group (control group).
Number of subjects: 552
Study 35649597 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-fatigue assessment group.
Number of subjects: 552
Study 32946806 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the left PFC
Number of subjects: 48
Study 32946806 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 48
Study 36036185 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation Based Education (SBE)
Number of subjects: 24
Study 36036185 — intervention group
Group type: COMPARATOR
Intervention: Conventional Education (CE)
Number of subjects: 24
Study 32811575 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin therapy
Number of subjects: 0
Study 32811575 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin therapy with SSRIs
Number of subjects: 0
Study 34755287 — intervention group
Group type: EXPERIMENTAL
Intervention: Quxie Capsule combined with conventional therapy (chemotherapy, radiotherapy, targeted therapy, supportive care)
Number of subjects: 60
Study 34755287 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with conventional therapy (chemotherapy, radiotherapy, targeted therapy, supportive care)
Number of subjects: 60
Study 34755287 — intervention group
Group type: EXPERIMENTAL
Intervention: Quxie Capsule in subgroup analysis (⩾second-line therapy, non-targeted therapy, RAS gene wild type, left-sided colon)
Number of subjects: 60
Study 34755287 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 33618683 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment for 2 years
Number of subjects: 560
Study 33618683 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 560
Study 32129208 — intervention group
Group type: EXPERIMENTAL
Intervention: Training based on Lazarus and Folkman transactional model
Number of subjects: 116
Study 32129208 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 116
Study 35947039 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 48
Study 35947039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 33367924 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy at 0.12 mJ/mm2, 2,000 impulses
Number of subjects: 89
Study 33367924 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy at 0.12 mJ/mm2, 4,000 impulses
Number of subjects: 89
Study 33367924 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy at 0.24 mJ/mm2, 2,000 impulses
Number of subjects: 89
Study 33367924 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy at 0.24 mJ/mm2, 4,000 impulses
Number of subjects: 89
Study 33367924 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 89
Study 32086006 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental training (four training sessions pushing away thin body pictures and pulling closer realistic pictures)
Number of subjects: 104
Study 32086006 — intervention group
Group type: COMPARATOR
Intervention: Placebo training (same stimuli shown with 50/50 contingency)
Number of subjects: 104
Study 32086006 — intervention group
Group type: COMPARATOR
Intervention: No training control condition
Number of subjects: 104
Study 32086006 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental training
Number of subjects: 104
Study 35181928 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment for overactive bladder
Number of subjects: 26
Study 34114250 — intervention group
Group type: EXPERIMENTAL
Intervention: Active MDMA (75-125 mg)
Number of subjects: 63
Study 34114250 — intervention group
Group type: COMPARATOR
Intervention: Placebo/control MDMA (0-40 mg)
Number of subjects: 63
Study 32195928 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (various types including simple acupuncture, fire needle, warm acupuncture, auriculo-acupuncture, electroacupuncture)
Number of subjects: 0
Study 32195928 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological agents (not specified)
Number of subjects: 0
Study 34380382 — intervention group
Group type: EXPERIMENTAL
Intervention: 1100 mg coffee berry extract
Number of subjects: 46
Study 34380382 — intervention group
Group type: EXPERIMENTAL
Intervention: 1100 mg coffee berry extract plus 275 mg apple extract
Number of subjects: 46
Study 34380382 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg coffee berry extract plus 275 mg apple extract
Number of subjects: 46
Study 34380382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 33172509 — intervention group
Group type: EXPERIMENTAL
Intervention: EEM group (eating at 19.00‐19.30 hours)
Number of subjects: 82
Study 33172509 — intervention group
Group type: COMPARATOR
Intervention: LEM group (eating at 22.30‐23.00 hours)
Number of subjects: 82
Study 33172509 — intervention group
Group type: EXPERIMENTAL
Intervention: EEM group
Number of subjects: 82
Study 33172509 — intervention group
Group type: COMPARATOR
Intervention: LEM group
Number of subjects: 82
Study 35649228 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion pump (HAIP) chemotherapy
Number of subjects: 0
Study 35649228 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug‐eluting beads coated with irinotecan transarterial chemoembolization
Number of subjects: 0
Study 35649228 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial radioembolization
Number of subjects: 0
Study 35649228 — intervention group
Group type: EXPERIMENTAL
Intervention: HAIP, transarterial chemoembolization, and transarterial radioembolization
Number of subjects: 0
Study 33035097 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (SNM) therapy
Number of subjects: 0
Study 33035097 — intervention group
Group type: EXPERIMENTAL
Intervention: Axonics SNM System®
Number of subjects: 0
Study 33035097 — intervention group
Group type: EXPERIMENTAL
Intervention: SNM therapy options
Number of subjects: 0
Study 35781432 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine (Septodont) with 2.5% sodium hypochlorite irrigation
Number of subjects: 90
Study 35781432 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-MTA White (Produits Dentaires) with 2.5% sodium hypochlorite irrigation
Number of subjects: 90
Study 35781432 — intervention group
Group type: EXPERIMENTAL
Intervention: K-Biocer (REKITA) with 2.5% sodium hypochlorite irrigation
Number of subjects: 90
Study 35781432 — intervention group
Group type: COMPARATOR
Intervention: Control group (irrigation not specified)
Number of subjects: 90
Study 34544939 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Itraconazole 200 mg
Number of subjects: 850
Study 34544939 — intervention group
Group type: COMPARATOR
Intervention: Liposomal Amphotericin B 3.0 mg/kg once daily
Number of subjects: 850
Study 35013898 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention in addition to standard care
Number of subjects: 82
Study 35013898 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 82
Study 32053522 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intravenous tranexamic acid (TXA) - 3 doses of 1,000 mg
Number of subjects: 100
Study 32053522 — intervention group
Group type: COMPARATOR
Intervention: Placebo - 3 doses of intravenous normal saline solution
Number of subjects: 100
Study 32053522 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intravenous tranexamic acid (TXA)
Number of subjects: 100
Study 32053522 — intervention group
Group type: COMPARATOR
Intervention: Placebo - intravenous normal saline solution
Number of subjects: 100
Study 35945094 — intervention group
Group type: EXPERIMENTAL
Intervention: a‐tDCS 1‐s Group (one daily a‐tDCS session)
Number of subjects: 30
Study 35945094 — intervention group
Group type: EXPERIMENTAL
Intervention: a‐tDCS 2‐s Group (two daily a‐tDCS sessions)
Number of subjects: 30
Study 35945094 — intervention group
Group type: COMPARATOR
Intervention: Group SHAM (one daily session with simulated current)
Number of subjects: 30
Study 33886519 — intervention group
Group type: EXPERIMENTAL
Intervention: Video curriculum
Number of subjects: 60
Study 33886519 — intervention group
Group type: COMPARATOR
Intervention: Reading group
Number of subjects: 60
Study 35485297 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise at 50% maximal voluntary isometric contraction (MVIC)
Number of subjects: 13
Study 35485297 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise at 75% maximal voluntary isometric contraction (MVIC)
Number of subjects: 13
Study 35485297 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise at 25% maximal voluntary isometric contraction (MVIC)
Number of subjects: 13
Study 35485297 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 50% and 75% MVIC
Number of subjects: 13
Study 35485297 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 25% and 50% MVIC
Number of subjects: 13
Study 35867804 — intervention group
Group type: EXPERIMENTAL
Intervention: istaroxime 1.0–1.5 μg/kg/min
Number of subjects: 60
Study 35867804 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 32827729 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg subcutaneously once at baseline
Number of subjects: 20
Study 32827729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 32827729 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 20
Study 35381034 — intervention group
Group type: EXPERIMENTAL
Intervention: Settlement Services Literacy (SSL) scale, validated through exploratory factor analysis (EFA) and confirmatory factor analysis (CFA).
Number of subjects: 653
Study 33065667 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmetatarsal base screw
Number of subjects: 16
Study 33065667 — intervention group
Group type: COMPARATOR
Intervention: Lisfranc screw
Number of subjects: 16
Study 35484991 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS) of the left dorsolateral prefrontal cortex (DLPFC) for 2 weeks.
Number of subjects: 58
Study 35484991 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation of the left dorsolateral prefrontal cortex for 2 weeks.
Number of subjects: 58
Study 32515840 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological mesh
Number of subjects: 24
Study 32515840 — intervention group
Group type: COMPARATOR
Intervention: Synthetic mesh
Number of subjects: 24
Study 35999487 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter torque tool
Number of subjects: 0
Study 35999487 — intervention group
Group type: COMPARATOR
Intervention: Standard ablation catheter without torque tool
Number of subjects: 0
Study 33599135 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular unloading for at least 30 minutes prior to coronary reperfusion
Number of subjects: 0
Study 33599135 — intervention group
Group type: COMPARATOR
Intervention: Current standard of care
Number of subjects: 0
Study 32276594 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline diet quality assessed using the Dietary Guideline Index (DGI-2013)
Number of subjects: 837
Study 32276594 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in DGI score over 5 years follow-up
Number of subjects: 837
Study 35762581 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT with cilostazol plus aspirin or clopidogrel
Number of subjects: 1197
Study 34227951 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Essential Newborn Care (EENC) implementation
Number of subjects: 259
Study 32960673 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics model incorporating handcrafted-signature, deep-signature, and SCC-Ag levels
Number of subjects: 190
Study 32960673 — intervention group
Group type: COMPARATOR
Intervention: Radiomics signature alone
Number of subjects: 190
Study 32960673 — intervention group
Group type: COMPARATOR
Intervention: SCC-Ag level alone
Number of subjects: 190
Study 34587328 — intervention group
Group type: EXPERIMENTAL
Intervention: House screening (HS) with permanently fixed fiberglass on all windows and doors
Number of subjects: 1200
Study 34587328 — intervention group
Group type: EXPERIMENTAL
Intervention: House screening (HS)
Number of subjects: 1200
Study 35413573 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics combined with enteral nutrition (EN)
Number of subjects: 81
Study 33172953 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel, targeted, youth‐focussed sleep intervention in addition to usual care
Number of subjects: 40
Study 33172953 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 40
Study 34165794 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomic nomogram based on multivariate logistic analysis
Number of subjects: 28150
Study 34165794 — intervention group
Group type: COMPARATOR
Intervention: Training set (n=18,766)
Number of subjects: 28150
Study 34165794 — intervention group
Group type: COMPARATOR
Intervention: Validation set (n=9,384)
Number of subjects: 28150
Study 33573017 — intervention group
Group type: EXPERIMENTAL
Intervention: POIBA intervention group (IG)
Number of subjects: 3624
Study 33573017 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (CG)
Number of subjects: 3624
Study 35438424 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal strength training (MST)
Number of subjects: 23
Study 35438424 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 23
Study 33639478 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months DAPT
Number of subjects: 1496
Study 33639478 — intervention group
Group type: COMPARATOR
Intervention: 12 months DAPT
Number of subjects: 1496
Study 32481297 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment in addition to basic treatment for sepsis
Number of subjects: 98
Study 32481297 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment for sepsis (Control group)
Number of subjects: 98
Study 36394533 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 0
Study 36394533 — intervention group
Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 0
Study 34600542 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist Independent Prescriber (PIP) intervention
Number of subjects: 25
Study 34600542 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 25
Study 35985506 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 106
Study 35985506 — intervention group
Group type: COMPARATOR
Intervention: Testosterone
Number of subjects: 106
Study 35985506 — intervention group
Group type: COMPARATOR
Intervention: Combination of Metformin and Testosterone
Number of subjects: 106
Study 35985506 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 106
Study 34251939 — intervention group
Group type: EXPERIMENTAL
Intervention: Y-chromosome-bearing sperm
Number of subjects: 50
Study 34251939 — intervention group
Group type: EXPERIMENTAL
Intervention: X-chromosome-bearing sperm
Number of subjects: 50
Study 32654539 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor V Leiden carriers (heterozygous or homozygous)
Number of subjects: 69681
Study 32654539 — intervention group
Group type: COMPARATOR
Intervention: Non-carriers of factor V Leiden
Number of subjects: 69681
Study 36128795 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational Wearable Infusor (IWI)
Number of subjects: 23
Study 36128795 — intervention group
Group type: COMPARATOR
Intervention: Crono S-PID-50 infusion pump (CP)
Number of subjects: 23
Study 32973057 — intervention group
Group type: EXPERIMENTAL
Intervention: Left bundle branch area pacing (LBBaP)
Number of subjects: 180
Study 32973057 — intervention group
Group type: COMPARATOR
Intervention: Biventricular pacing (Bi-V)
Number of subjects: 180
Study 35042375 — intervention group
Group type: EXPERIMENTAL
Intervention: Dislike condition
Number of subjects: 276
Study 35042375 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonconsent condition
Number of subjects: 276
Study 35042375 — intervention group
Group type: EXPERIMENTAL
Intervention: Said nothing condition
Number of subjects: 276
Study 33569807 — intervention group
Group type: EXPERIMENTAL
Intervention: GTR, BPBM, and PRF
Number of subjects: 14
Study 33569807 — intervention group
Group type: COMPARATOR
Intervention: GTR and BPBM
Number of subjects: 14
Study 33546534 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-dermal Platelet Rich Plasma (PRP) 1 ml monthly for 3 months
Number of subjects: 92
Study 33546534 — intervention group
Group type: COMPARATOR
Intervention: 50% Trichloracetic Acid (TCA) applied by CROSS technique monthly for 3 months
Number of subjects: 92
Study 35658059 — intervention group
Group type: EXPERIMENTAL
Intervention: Cingulate tDCS
Number of subjects: 11
Study 35658059 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 11
Study 34550034 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg orally once daily
Number of subjects: 228
Study 34550034 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 4000 AxaIU (0.4 mL) subcutaneously once daily
Number of subjects: 228
Study 32102687 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-cut titanium-coated polypropylene mesh
Number of subjects: 312
Study 32102687 — intervention group
Group type: COMPARATOR
Intervention: Mesh kit
Number of subjects: 312
Study 33038432 — intervention group
Group type: EXPERIMENTAL
Intervention: Emricasan 5 mg
Number of subjects: 217
Study 33038432 — intervention group
Group type: EXPERIMENTAL
Intervention: Emricasan 25 mg
Number of subjects: 217
Study 33038432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 33038432 — intervention group
Group type: EXPERIMENTAL
Intervention: Emricasan (both doses)
Number of subjects: 217
Study 33008301 — intervention group
Group type: COMPARATOR
Intervention: Kato-Katz (KK) method
Number of subjects: 320
Study 33008301 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time PCR
Number of subjects: 320
Study 33008301 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxidectin
Number of subjects: 320
Study 33008301 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxidectin + Tribendimidine
Number of subjects: 320
Study 33008301 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxidectin + Albendazole
Number of subjects: 320
Study 33008301 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole + Oxantel pamoate
Number of subjects: 320
Study 35241779 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (7.5–45 mg/day)
Number of subjects: 30
Study 35241779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 35241779 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 30
Study 35897119 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety planning and telephone follow-up intervention (SAFETEL)
Number of subjects: 120
Study 35897119 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 120
Study 33285143 — intervention group
Group type: EXPERIMENTAL
Intervention: mPOCT for influenza
Number of subjects: 613
Study 33285143 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical care (control group)
Number of subjects: 613
Study 35831082 — intervention group
Group type: EXPERIMENTAL
Intervention: CLEAN Meds intervention (short list of essential medicines)
Number of subjects: 379
Study 33300880 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) treatment on the intervention side (axilla or groin)
Number of subjects: 17